Antibodies that specifically react with seroreactive regions on HPV 16 proteins E1 and E2

Abstract

The invention relates to seroreactive regions on the E1 and E2 proteins of human papillomavirus 16 (HPV 16). The invention also relates to a vaccine that contains peptides comprising at least one seroreactive region of the E1 and/or E2 proteins. The invention likewise embraces compositions for diagnostic purposes, which contain peptides with the seroreactive regions. Further, the invention relates to antibodies that bind to seroreactive regions of the E1 and/or E2 proteins of HPV 16, and compositions comprising such antibodies, which can be used for diagnostic purposes.

What is claimed is:  
     
       1. An isolated antibody that binds to an amino acid sequence present in SEQ ID NO:15. 
     
     
       2. The antibody of  claim 1 , wherein the antibody detects or identifies the E2 protein of human papilloma virus 16 (HPV16). 
     
     
       3. A composition comprising the antibody of  claim 1  and an antibody binding buffer. 
     
     
       4. The composition of  claim 3 , which is a diagnostic composition. 
     
     
       5. The composition of  claim 4 , wherein the composition is used for identifying, diagnosing, or detecting HPV 16 infection. 
     
     
       6. A monoclonal antibody that binds to an amino acid sequence present in SEQ ID NO:15. 
     
     
       7. The antibody of  claim 6 , wherein the antibody detects or identifies the E2 protein of human papilloma virus 16 (HPV16). 
     
     
       8. A composition comprising the antibody of  claim 6  and an antibody binding buffer. 
     
     
       9. The composition of  claim 8 , which is a diagnostic composition. 
     
     
       10. The composition of  claim 8 , wherein the composition is used for identifying, diagnosing, or detecting HPV 16 infection. 
     
     
       11. A method of identifying, diagnosing, or detecting HPV 16 infection, said method comprising 
       contacting a sample from a human suspected of being infected with HPV 16 with an isolated antibody that binds to an amino acid sequence present in SEQ ID NO:15, and  
       detecting binding of said antibody to said amino acid sequence,  
       wherein binding indicates an HPV 16 infection.  
     
     
       12. The method of  claim 11 , wherein said detecting is by enzyme linked immunosorbent assay (ELISA). 
     
     
       13. The method of  claim 11 , wherein said method detects binding of said antibody with the E2 protein of HPV 16. 
     
     
       14. A method of identifying, diagnosing, or detecting HPV 16 infection, said method comprising 
       contacting a sample from a human suspected of being infected with HPV 16 with a monoclonal antibody that binds to an amino acid sequence present in SEQ ID NO:15, and  
       detecting binding of said antibody to said amino acid sequence,  
       wherein binding indicates an HPV 16 infection.  
     
     
       15. The method of  claim 14 , wherein said detecting is by enzyme linked immunosorbent assay (ELISA). 
     
     
       16. The method of  claim 14 , wherein said method detects binding of said antibody with the E2 protein of HPV 16.